Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Brain Neoplasms 10Carcinoma, Hepatocellular 9Neoplasm Metastasis 7Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Breast Neoplasms 3Glioblastoma 2Adenocarcinoma of Lung 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Radiotherapy 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Glioma 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1

Interventions

veliparib 1bavituximab 1avatrombopag 1Sorafenib 1Radiotherapy 1Radiosurgery 1Paclitaxel 1Immunotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liver Diseases × Radiosurgery × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡